Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
In this study, we defined the role of peroxisome proliferator-activated receptor β/δ (PPARδ) in metabolic homeostasis by using subtype selective agonists. Analysis of rat L6 myotubes treated with the PPARδ subtype-selective agonist, GW501516, by the Affymetrix oligonucleotide microarrays revealed that PPARδ controls fatty acid oxidation by regulating genes involved in fatty acid transport, β-oxidation, and mitochondrial respiration. Similar PPARδ-mediated gene activation was observed in the skeletal muscle of GW501516-treated mice. Accordingly, GW501516 treatment induced fatty acid β-oxidation in L6 myotubes as well as in mouse skeletal muscles. Administration of GW501516 to mice fed a high-fat diet ameliorated diet-induced obesity and insulin resistance, an effect accompanied by enhanced metabolic rate and fatty acid β-oxidation, proliferation of mitochondria, and a marked reduction of lipid droplets in skeletal muscles. Despite a modest body weight change relative to vehicle-treated mice, GW501516 treatment also markedly improved diabetes as revealed by the decrease in plasma glucose and blood insulin levels in genetically obese ob / ob mice. These data suggest that PPARδ is pivotal to control the program for fatty acid oxidation in the skeletal muscle, thereby ameliorating obesity and insulin resistance through its activation in obese animals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, SIRT1 activators like resveratrol and NAD+ precursors have been shown to enhance mitochondrial biogenesis and oxidative metabolism, leading to improved muscle function and recovery”
From Exercise-Induced Muscle–Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging (2025) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, PPAR agonists, such as pioglitazone (PPAR-γ) and the investigational GW501516 (PPAR-δ), have been shown in clinical and preclinical studies to enhance lipid metabolism and insulin sensitivity”
From Exercise-Induced Muscle–Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging (2025) · cites this paper as [112]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treating mice with PPARα or PPARβ/δ agonists also induces, either directly or indirectly, an increase in whole body oxygen consumption without affecting caloric intake, thus accounting for lower rates of weight gain in response to high fat feeding (Guerre-Millo et al., 2000; Tanaka et al., 2003).”
From Lipid-Induced Mitochondrial Stress and Insulin Action in Muscle (2012) · cites this paper as Tanaka et al., 2003
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Obesity and the regulation of energy balance
Spiegelman, B. M., & Flier, J. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00240-9 · Cited by 2,398
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Forman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116
Mitochondrial dysfunction in the elderly: possible role in insulin resistance
Petersen, K. F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D. L., DiPietro, L., Cline, G. W., & Shulman, G. I. (2003) · Science · doi:10.1126/science.1082889 · Cited by 2,107
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766
Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00269-1 · Cited by 1,296
Research works printed but not linked: 1
- Dressel, U., Allen, T. L., Pippal, J. B., Rohde, P. R., Lau, P. & Muscat, G. E. (2003) Mol Endocrinol., in press. [DOI] [PubMed]
Cited by
Items 301–400 of 860
Transcriptional activators HAP/NF-Y rescue a cytochrome c oxidase defect in yeast and human cells
Fontanesi, F., Jin, C., Tzagoloff, A., & Barrientos, A. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm349 · Cited by 58
Quintela, A. M., Jiménez, R., Gómez‐Guzmán, M., Zarzuelo-Romero, M. J., Galindo, P., Sánchez, M., Vargas, F., Cogolludo, A. L., Tamargo, J. L., Pérez‐Vizcaíno, F., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.05.045 · Cited by 64
Fürnsinn, C., Willson, T. M., & Brunmair, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0492-0 · Cited by 59
Vänttinen, M., Nuutila, P., Kuulasmaa, T., Pihlajamäki, J., Hällsten, K., Virtanen, K. A., Läutamaki, R., Peltoniemi, P., Takala, T., Viljanen, A. P. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3587 · Cited by 57
Zaveri, N. T., & Murphy, B. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00063-8 · Cited by 64
Perez, D. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.652152 · Cited by 69
PPAR ligands: Potential therapies for metabolic syndrome
Akiyama, T. E., Meinke, P. T., & Berger, J. P. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0067-3 · Cited by 62
Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
Sharma, M., Premkumar, M., Kulkarni, A. V., Kumar, P., Reddy, D. N., & Rao, N. P. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00055 · Cited by 61
In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
He, B. K., Ning, Z. Q., Li, Z. B., Shan, S., Pan, D. S., Ko, B. C. B., Li, P. P., Shen, Z. F., Dou, G. F., Zhang, B. L., et al. (2012) · PPAR Research · doi:10.1155/2012/546548 · Cited by 53
TNF-α inhibits PPARβ/δ activity and SIRT1 expression through NF-κB in human adipocytes
Serrano, L., Chacón, M. R., Maymó‐Masip, E., Barroso, E., Salvadó, L., Wabitsch, M., Garrido‐Sánchez, L., Tinahones, F. J., Palomer, X., Vendrell, J. J., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.05.006 · Cited by 68
Beneficial Effects of Exercise on Muscle Mitochondrial Function in Diabetes Mellitus
Lumini‐Oliveira, J., Magalhães, J., Oliveira, P. J., & Ascensão, A. A. M. R. (2008) · Sports Medicine · doi:10.2165/00007256-200838090-00003 · Cited by 62
Hautala, A. J., Leon, A. S., Skinner, J. S., Rao, D. C., Bouchard, C., & Rankinen, T. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01092.2006 · Cited by 61
Yuan, H., Lu, J., Xiao, J., Upadhyay, G., Umans, R., Kallakury, B., Yin, Y., Fant, M. E., Kopelovich, L., & Glazer, R. I. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0322 · Cited by 60
Toral, M., Romero, M., Jiménez, R., Mahmoud, A. M., Barroso, E., Gómez‐Guzmán, M., Sánchez, M., Cogolludo, A. L., García‐Redondo, A. B., Briones, A. M., et al. (2015) · Clinical Science · doi:10.1042/cs20150111 · Cited by 61
The secret messages between mitochondria and nucleus in muscle cell biology
Soledad, R. B., Charles, S., & Das, S. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.03.019 · Cited by 55
Effects of interleukin-15 on lipid oxidation
Almendro, V., Busquets, S., Ametller, E., Carbó, N., Figueras, M., Fuster, G., Argilés, J. M. A., & López-Soriano, F. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2005.12.006 · Cited by 57
Regulatory functions of PPARβ in metabolism: implications for the treatment of metabolic syndrome
Grimaldi, P. A. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.006 · Cited by 60
The Functions of PPARs in Aging and Longevity
Erol, A. (2007) · PPAR Research · doi:10.1155/2007/39654 · Cited by 54
Prolonged exposure to insulin suppresses mitochondrial production in primary hepatocytes.
Liu, H.-Y., Yehuda-Shnaidman, E., Hong, T., Han, J., Pi, J., Liu, Z., & Cao, W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807992200 · Cited by 54
Peroxisome proliferator‐activated receptors in cardiac energy metabolism and cardiovascular disease
Ajith, T. A., & Jayakumar, T. G. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12579 · Cited by 58
Jang, W. S., & Choung, S. Y. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/492807 · Cited by 54
Mitochondrial ion transport pathways: Role in metabolic diseases
Cardoso, A. R., Queliconi, B. B., & Kowaltowski, A. J. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.12.017 · Cited by 63
Deubiquitinase OTUD3 regulates metabolism homeostasis in response to nutritional stresses
Zhou, N., Qi, H., Liu, J., Zhang, G., Liu, J., Liu, N., Zhu, M., Zhao, X., Song, C., Zhou, Z. C., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.005 · Cited by 55
Vaticanol C, a resveratrol tetramer, activates PPARα and PPARβ/δ in vitro and in vivo
Tsukamoto, T., Nakata, R., Tamura, E., Kosuge, Y., Kariya, A., Katsukawa, M., Mishima, S., Ito, T., Iinuma, M., Akao, Y., et al. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-46 · Cited by 59
Goto, T., Kim, Y.-I., Funakoshi, K., Teraminami, A., Uemura, T., Hirai, S., Lee, J.-Y., Makishima, M., Nakata, R., Inoue, H., et al. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00061.2011 · Cited by 57
Robitaille, J., Gaudet, D., Përusse, L., & Vohl, M. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803450 · Cited by 58
Endurance Exercise Mimetics in Skeletal Muscle
Matsakas, A., & Narkar, V. A. (2010) · Current Sports Medicine Reports · doi:10.1249/jsr.0b013e3181e93938 · Cited by 50
Houten, S. M., Chegary, M., Brinke, H. T., Wijnen, W. J., Glatz, J. F. C., Luiken, J. J. F. P., Wijburg, F. A., & Wanders, R. J. A. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-9066-x · Cited by 62
Sato, N., Kaneko, M., Tamura, M., & Kurumatani, H. (2010) · Diabetes · doi:10.2337/db09-1432 · Cited by 54
Crosstalk between PPARs and gut microbiota in NAFLD
Wu, L., Li, J., Feng, J., Ji, J., Yu, Q., Li, Y., Zheng, Y., Dai, W., Wu, J., & Guo, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111255 · Cited by 53
The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome
Huang, T. H.-W., Teoh, A. W., Beilun, L., Lin, D. S.-H., & Roufogalis, B. D. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.03.020 · Cited by 54
Exploration of PPAR functions by microarray technology—A paradigm for nutrigenomics
Bünger, M., Hooiveld, G. J. E. J., Kersten, S., & Müller, M. M. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.004 · Cited by 61
Mitochondrial Dysfunction and Diabetes: Is Mitochondrial Transfer a Friend or Foe?
Montgomery, M. K. (2019) · Biology · doi:10.3390/biology8020033 · Cited by 66
Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease
Steensels, S., Qiao, J., & Ersoy, B. A. (2020) · Metabolites · doi:10.3390/metabo10070283 · Cited by 58
Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease
Pan, J., Zhou, W., Xu, R., Xing, L., Ji, G., & Dang, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113127 · Cited by 52
The Role of PPARs in Breast Cancer
Zhao, B., Xin, Z., Ren, P., & Wu, H. (2022) · Cells · doi:10.3390/cells12010130 · Cited by 60
de Lange, P., Lombardi, A., Silvestri, E., Goglia, F., Lanni, A., & Moreno, M. (2008) · PPAR Research · doi:10.1155/2008/172676 · Cited by 67
Effects of IL-15 on rat brown adipose tissue: Uncoupling proteins and PPARs
Almendro, V., Fuster, G., Busquets, S., Ametller, E., Figueras, M., Argilés, J. M., & López‐Soriano, F. J. (2008) · Obesity · doi:10.1038/oby.2007.47 · Cited by 49
Zarei, M., Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154342 · Cited by 53
Epple, R., Cow, C., Yongping, X., Azimioara, M. D., Russo, R., Wang, X., Wityak, J., Karanewsky, D. S., Tuntland, T., Nguyen-Tran, V. T. B., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9007399 · Cited by 53
Luo, H., Wei, H., Huang, F., Zhou, Z., Jiang, S., & Peng, J. (2009) · Lipids · doi:10.1007/s11745-009-3346-y · Cited by 55
Lipina, C., Irving, A. J., & Hundal, H. S. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00100.2014 · Cited by 55
Chanséaume, E., & Morio, B. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10010306 · Cited by 55
Eynon, N., Meckel, Y., Alves, A. J., Yamin, C., Sagiv, M. S., Goldhammer, E., & Sagiv, M. (2009) · Experimental Physiology · doi:10.1113/expphysiol.2009.049668 · Cited by 53
Holloway, G. P., Perry, C. G. R., Thrush, A. B., Heigenhauser, G. J. F., Dyck, D. J., Bonen, A., & Spriet, L. L. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00726.2007 · Cited by 48
Interleukin‐15 in obesity and metabolic dysfunction: current understanding and future perspectives
Duan, Y., Li, F., Wang, W., Guo, Q., Wen, C., Li, Y., & Yin, Y. (2017) · Obesity Reviews · doi:10.1111/obr.12567 · Cited by 47
New Therapeutic Target for Metabolic Syndrome: PPAR.DELTA.
Takahashi, S., Tanaka, T., & Sakai, J. (2007) · Endocrine Journal · doi:10.1507/endocrj.kr-99 · Cited by 50
Self-citationMyers, S., Wang, S.-C., & Muscat, G. E. O. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601941200 · Cited by 49
Akinrotimi, O., Riessen, R., VanDuyne, P., Park, J. E., Lee, Y., Wong, L., Zavacki, A. M., Schoonjans, K., & Anakk, S. (2017) · Hepatology · doi:10.1002/hep.29305 · Cited by 51
Hu, W.-B., Zhao, J., Chen, H., Xiong, L., & Wang, W. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.07.020 · Cited by 46
Lunde, I. G., Ekmark, M., Rana, Z. A., Buonanno, A., & Gundersen, K. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.133025 · Cited by 45
Osteoarthritis: Role of Peroxisome Proliferator-Activated Receptors
Sheng, W., Wang, Q., Qin, H., Cao, S., Wei, Y., Weng, J., Yu, F., & Zeng, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713137 · Cited by 53
Ratneswaran, A., LeBlanc, E. A., Walser, E., Welch, I. D., Mort, J. S., Borradaile, N. M., & Beier, F. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38915 · Cited by 48
Matsuba, I., Matsuba, R., Ishibashi, S., Yamashita, S., Arai, H., Yokote, K., Suganami, H., & Araki, E. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12845 · Cited by 43
Oskouei, Z., Akaberi, M., & Hosseinzadeh, H. (2018) · PubMed Central · doi:10.22038/ijbms.2018.31703.7630 · Cited by 54
Crossland, H., Constantin‐Teodosiu, D., & Greenhaff, P. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189775 · Cited by 53
A metabolomic study of the PPARδ agonist GW501516 for enhancing running endurance in Kunming mice
Chen, W., Gao, R., Xie, X., Zheng, Z., Li, H., Song, L., Dong, F., & Wang, L. (2015) · Scientific Reports · doi:10.1038/srep09884 · Cited by 55
Flees, J. J., Ganguly, B., & Dridi, S. (2020) · Poultry Science · doi:10.1016/j.psj.2020.12.060 · Cited by 52
Grarup, N., Albrechtsen, A., Ek, J., Borch‐Johnsen, K., Jørgensen, T., Schmitz, O., Hansen, T. F., & Pedersen, O. B. (2007) · Diabetologia · doi:10.1007/s00125-007-0668-2 · Cited by 46
Improved insulin sensitivity and islet function after PPARδ activation in diabetic db/db mice
Winzell, M. S., Wulff, E. M., Olsen, G. S., Sauerberg, P., Gotfredsen, C. F., & Åhrén, B. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.053 · Cited by 45
Paterniti, I., Esposito, E., Mazzon, E., Galuppo, M., Paola, R. D., Bramanti, P., Kapoor, A., Thiemermann, C., & Cuzzocrea, S. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.165605 · Cited by 42
RetractedBenetti, E., Mastrocola, R., Rogazzo, M., Chiazza, F., Aragno, M., Fantozzi, R., Collino, M., & Minetto, M. A. (2013) · Mediators of Inflammation · doi:10.1155/2013/509502 · Cited by 43
Identification of a PPARδ agonist with partial agonistic activity on PPARγ
Connors, R., Wang, Z., Harrison, M., Zhang, A., Wanska, M., Hiscock, S., Fox, B. M., Dore, M., Labelle, M., Sudom, A. M., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.151 · Cited by 49
Wang, J., Wei, Y., Wang, D., Chan, L. L., & Dai, J. (2007) · Ecotoxicology · doi:10.1007/s10646-007-0187-4 · Cited by 48
Emerging roles of PPARδ in metabolism
Seedorf, U., & Aberle, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.017 · Cited by 55
Tero-Vescan, A., Degens, H., Matsakas, A., Ștefănescu, R., Ősz, B. E., & Slevin, M. (2025) · Pharmaceuticals · doi:10.3390/ph18081222 · Cited by 44
“Similarly, SIRT1 activators like resveratrol and NAD + pre-cursors have been shown to enhance mitochondrial biogenesis and oxidative metabolism, leading to improved muscle function and recovery [112,118,126].”
Ngoc, H. L., Shin, S., Tu, T. H., Kim, C.-S., Kang, J., Goto, T., Teruo, K., Han, S. N., & Yu, R. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf303548k · Cited by 42
The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease
Chiang, M., Chern, Y., & Juo, C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.05.006 · Cited by 46
Parent, R., & Beretta, L. (2008) · Genome biology · doi:10.1186/gb-2008-9-1-r19 · Cited by 46
Nakano, S., Inada, Y., Masuzaki, H., Tanaka, T., Yasue, S., Ishii, T., Arai, N., Ebihara, K., Hosoda, K., Maruyama, K., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00340.2006 · Cited by 44
Self-citationOhguchi, H., Tanaka, T., Uchida, A., Magoori, K., Kudo, H., Kim, I., Daigo, K., Sakakibara, I., Okamura, M., Harigae, H., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02154-07 · Cited by 46
Self-citationKasuga, J.-I., Yamasaki, D., Araya, Y., Nakagawa, A., Makishima, M., Doi, T., Hashimoto, Y., & Miyachi, H. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.09.001 · Cited by 44
Self-citationKasuga, J.-I., Nakagome, I., Aoyama, A., Sako, K., Ishizawa, M., Ogura, M., Makishima, M., Hirono, S., Hashimoto, Y., & Miyachi, H. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.05.023 · Cited by 47
Jucker, B. M., Doe, C. P. A., Schnackenberg, C. G., Olzinski, A. R., Maniscalco, K., Williams, C., Hu, T. C., Lenhard, S. C., Costell, M. H., Bernard, R., et al. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31804b4163 · Cited by 47
Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus
Salvadó, L., Serrano, L., Barroso, E., Palomer, X., & Vázquez‐Carrera, M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.658370 · Cited by 49
Orphan Nuclear Receptors as Targets for Drug Development
Mukherjee, S., & Mani, S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0117-7 · Cited by 47
Bility, M. T., Devlin-Durante, M. K., Blazanin, N., Glick, A. B., Ward, J. M., Kang, B. H., Kennett, M. J., Gonzalez, F. J., & Peters, J. M. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn219 · Cited by 42
Flavan-3-ol fraction from cocoa powder promotes mitochondrial biogenesis in skeletal muscle in mice
Watanabe, N., Inagawa, K., Shibata, M., & Osakabe, N. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-64 · Cited by 44
Kors, L., Rampanelli, E., Stokman, G., Butter, L. M., Held, N. M., Claessen, N., Larsen, P. W. B., Verheij, J., Zuurbier, C. J., Liebisch, G., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.003 · Cited by 52
Goto, T. (2018) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2018.1559025 · Cited by 40
Escher, S. E., Aguayo‐Orozco, A., Benfenati, E., Bitsch, A., Braunbeck, T. A., Brotzmann, K., Bois, F. Y., van der Burg, B., Castel, J., Exner, T. E., et al. (2021) · Toxicology in Vitro · doi:10.1016/j.tiv.2021.105269 · Cited by 45
Investigational PPAR-γ agonists for the treatment of Type 2 diabetes
Savkur, R. S., & Miller, A. R. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.7.763 · Cited by 43
Induction of Metastatic Gastric Cancer by Peroxisome Proliferator-Activated Receptorδ Activation
Pollock, C. B., Rodriguez, O., Martin, P. L., Albanese, C., Li, X., Kopelovich, L., & Glazer, R. I. (2010) · PPAR Research · doi:10.1155/2010/571783 · Cited by 40
PPAR‐δ in Vascular Pathophysiology
Wang, N. (2008) · PPAR Research · doi:10.1155/2008/164163 · Cited by 40
Parent, R., Kolippakkam, D. N., Booth, G. C., & Beretta, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3640 · Cited by 41
Peroxisome proliferator-activated receptors: a therapeutic target in COPD?: Fig. 1—
Remels, A. H., Gosker, H. R., Schrauwen, P., Langen, R. C., & Schols, A. M. (2008) · European Respiratory Journal · doi:10.1183/09031936.00068207 · Cited by 40
de Lange, P., Feola, A., Ragni, M., Senese, R., Moreno, M., Lombardi, A., Silvestri, E., Amat, R., Villarroya, F., Goglia, F., et al. (2007) · Endocrinology · doi:10.1210/en.2007-0206 · Cited by 40
Lipids, Lipoproteins, and Peroxisome Proliferator Activated Receptor–δ
Sprecher, D. L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.08.009 · Cited by 51
Choi, K. C., Lee, S. Y., Yoo, H. J., Ryu, O., Lee, K. W., Kim, S. M., Baik, S. H., & Choi, K. M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.114 · Cited by 40
Cinnamaldehyde Contributes to Insulin Sensitivity by Activating PPARδ, PPARγ, and RXR
Li, J.-E., Futawaka, K., Yamamoto, H., Kasahara, M., Tagami, T., Liu, T., & Moriyama, K. (2015) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x15500512 · Cited by 43
Xu, Y., Kume, S., Tanaka, Y., Isshiki, K., Araki, S., Chin‒Kanasaki, M., Sugimoto, T., Koya, D., Haneda, M., Sugaya, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025271 · Cited by 43
Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies
Heald, M., & Cawthorne, M. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_2 · Cited by 43
Zizola, C. F., Kennel, P. J., Akashi, H., Ji, R., Castillero, E., George, I., Homma, S., & Schulze, P. C. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00679.2014 · Cited by 41
Peroxisome proliferator-activated receptor β/δ as a therapeutic target for metabolic diseases
Bedu, E., Wahli, W., & Desvergne, B. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.861 · Cited by 46
1,3,5-Trisubstituted aryls as highly selective PPARδ agonists
Epple, R., Azimioara, M. D., Russo, R., Bursulaya, B. D., Tian, S., Gerken, A., & Iskandar, M. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.02.079 · Cited by 39
Peroxisome proliferator‐activated receptors as therapeutic target for cancer
Wang, Y., Lei, F., Lin, Y., Han, Y., Yang, L., & Tan, H. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17931 · Cited by 53
Barlaka, E., Galatou, E., Mellidis, K., Ravíngerová, T., & Lazou, A. (2016) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12166 · Cited by 41
Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
Xiao, Y., Kim, M., & Lazar, M. A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101119 · Cited by 43
Johnson, T. E., Zhang, X. D., Shi, S., & Umbenhauer, D. R. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2005.03.004 · Cited by 38
Mahmoud, A. M., Alexander, M. Y., Tutar, Y., Wilkinson, F. L., & Venditti, A. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2508909 · Cited by 38
Metadata
- Authors
- Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., Watanabe, Y., Uchiyama, Y., Sumi, K., Iguchi, H., Ito, S., Doi, T., Hamakubo, T., Naito, M., Auwerx, J., Yanagisawa, M., Kodama, T., & Sakai, J.
- Affiliations
- Tohoku University (JP)
- Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo 153-8904, Japan; Pharmacology II, Department of Research and Development, Grelan Pharmaceutical Co. Ltd., Tokyo 205-8501, Japan; Division of Nephrology, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan; Yanagisawa Orphan Receptor Project, Exploratory Research for Advanced Technology, Japan...
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-12-15
- Volume
- 100
- Issue
- 26
- Pages
- 15924-15929
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC307669
- OpenAlex
- W1982027543
- Cited by
- 832
- References
- 18
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 16 · 2023: 16 · 2022: 21 · 2021: 32 · 2020: 36 · 2019: 13 · 2018: 42 · 2017: 28 · 2016: 25 · 2015: 33 · 2014: 36 · 2013: 35 · 2012: 39
- FWCI
- 16.00
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- PPARδ, fatty acid beta-oxidation, skeletal muscle, metabolic syndrome, GW501516, insulin resistance, obesity, high-fat diet, mitochondrial respiration, fatty acid uptake, lipid droplets, diabetes mellitus, ob/ob mice, metabolic rate
- MeSH terms
- Animals, Dimethyl Sulfoxide, Enzymes, Fatty Acids, Nonesterified, Insulin Resistance, Liver, Male, Mice, Inbred C57BL, Mice, Obese, Oxidation-Reduction, Thiazoles, Transcription Factors, Receptors, Cytoplasmic and Nuclear, Muscle, Skeletal, Metabolic Syndrome, Lipid Metabolism, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.